Data bolsters scientific rationale for clinical evaluation of
GMI-1359 in AML patients harboring aberrant FLT3 and in patients with
GAITHERSBURG, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that pre-clinical
research demonstrating the potential of its third drug candidate, GMI-1359,
will be presented at the American
Association for Cancer Research (AACR) Annual Meeting 2016 in New
Orleans. An oral presentation and a poster will highlight data on
GMI-1359, a potent dual antagonist of both E-selectin and CXCR4,
demonstrating anti-tumor activity in preclinical models of pancreatic
cancer and acute myeloid leukemia (AML), respectively. In a pancreatic
cancer model, GMI-1359 showed significant disruption of the tumor
microenvironment and inhibited tumor metastasis. In an AML model, while
either GMI-1359 or sorafenib alone reduced tumor burden, antitumor
activity was significantly enhanced when GMI-1359 was given in
combination with sorafenib, over either treatment alone. The AACR Annual
Meeting 2016 takes place from April 16 to 20, 2016, at the Ernest N.
Morial Convention Center.
"Our data provides additional preclinical support for initiating
clinical trials of GMI-1359 in both FLT3 mutated AML and pancreatic
cancer. GMI-1359's ability to disrupt the tumor microenvironment and
known pathways of cancer cell trafficking has great potential to improve
survival in some of the most challenging cancers," said John
Magnani, Ph.D., GlycoMimetics Vice President and Chief Scientific Officer.
"We are completing the IND-enabling program for this promising agent and
plan to file an IND later this year."
The AACR presentations from GlycoMimetics, including abstract title,
session times, and locations, include the following:
Steele, M.M., et al. "A Small Molecule Glycomimetic Antagonist of
E-Selectin and CXCR4 (GMI-1359) Delays Pancreatic Tumor Metastasis and
Significantly Alters the Pancreatic Tumor Microenvironment"
[MiniSymposium: Immunomodulation in cancer. MS.TB06.01, Sunday, April
17, 2016, 4:15-6:15 p.m. Central Time] Abstract 902
Zhang, W., et al. "Targeting E-selectin/CXCR4 with GMI-1359
Effectively Mobilizes Bone Marrow Leukemia Cells and Enhances FLT3
Inhibitor-induced Anti-leukemia Efficacy in a Murine Acute Myeloid
Leukemia Model" [Hematological Environment - Poster Session
PO.TB06.04, Tuesday, April 19, 2016, 8:00 a.m.-12:00 p.m. Central
Time] Abstract 3284
About GlycoMimetics, Inc.
GlycoMimetics is a Phase 3 clinical-stage biotechnology company
developing its proprietary drug candidate, rivipansel, a pan-selectin
antagonist, for the treatment of vaso-occlusive crisis in sickle cell
disease, through its strategic partner, Pfizer. GlycoMimetics's
wholly-owned lead drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated for AML and other blood disorders, for which
differentiating initial data from an ongoing Phase 1/2 study have been
announced. A third candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist, is being readied for the clinic in 2016. Fueling the
pipeline, an in-house discovery and research group is focused on novel
glycomimetic drugs to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role. Learn more at www.glycomimetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160317005447/en/
Shari Annes, 650-888-0902
News Provided by Acquire Media